Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate stomach problems. PPIs are activated in the acid-producing cells of the stomach, where they block acid production. Researchers at the German Cancer Research Center (DKFZ) made the surprising discovery that zinc-carrying proteins, which are found in all cells, can also activate PPIs – without the presence of gastric acid. The result could be a key to understanding the side effects of PPIs.

Researchers including those from the University of Tokyo developed Deep Nanometry, an analytical technique combining advanced optical equipment with a noise removal algorithm based on unsupervised deep learning. Deep Nanometry can analyze nanoparticles in medical samples at high speed, making it possible to accurately detect even trace amounts of rare particles. This has proven its potential for detecting extracellular vesicles indicating early signs of colon cancer, and it is hoped that it can be applied to other medical and industrial fields.

The management of non-small cell lung cancer (NSCLC) has recently evolved and is highly dependent on its staging, molecular characteristics, and patient condition. The preoperative stage of NSCLC remains the primary factor in determining treatment and overall prognosis.

Thoracic surgery has made enormous progress in the last decade thanks to minimally invasive procedures, intra-operative imaging, artificial intelligence (AI), and technological evolution, moving towards precision surgery.

In this new scenario, it is appropriate to evaluate the potential resectability of T4-NSCLC that invades the thoracic aorta (T4invAo) and reasonable to plan radical surgery in these patients.

Endovascular treatment is the gold standard for managing thoracic aortic pathology. This minimally invasive approach reduces perioperative morbidity and mortality rates compared to traditional open surgery. The hybrid operating room (HOR) plays a fundamental role in this context, allowing for the best technical strategy in a “one-stop” procedure.

Texas Children’s Hospital and The University of Texas MD Anderson Cancer Center have announced a transformational collaboration dedicated solely to pediatric cancer care. Approved by the Texas Children’s Board of Trustees and the UT System Board of Regents, this new, first-of-its-kind joint venture will unite the nation’s largest comprehensive pediatric system and a top pediatric cancer program with the nation’s leading comprehensive cancer center. The collaboration has a single mission: to end childhood cancer.

The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital have announced a transformational collaboration dedicated solely to pediatric cancer care. The collaboration has a single mission: to end childhood cancer. 

The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to advance new breakthroughs in discovery, translational, clinical and prevention science. In addition, CPRIT awarded $2 million for the recruitment of one first-time, tenure-track faculty member.

Kimberly Stegmaier, MD, was named Chair of Pediatric Oncology at Dana-Farber Cancer Institute and Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital, in an announcement made today. Her appointment is effective April 1, 2025.

Clinical research by Dana-Farber scientists suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy. Navtemadlin is an MDM2 inhibitor that can help to kill cancer cells by boosting the activity of p53, a protein that controls cell growth and induces cell death in response to DNA damage. In lab experiments, the researchers found that navtemadlin was one of the best drugs at killing glioblastoma cells with intact, non-mutant p53.